Abivax (AAVXF) Other Non-Current Assets (2022 - 2025)
Abivax (AAVXF) posted Other Non-Current Assets of $727527.2 for Q4 2025, down 19.39% on a QoQ basis from $902516.8 in Q1 2025, and down 28.18% year-over-year from $1.0 million in Q4 2024.
Analysis
Abivax (AAVXF) Other Non-Current Assets (2022 - 2025) Analysis & Trends
Abivax has reported Other Non-Current Assets for 4 years, with the latest figure at $727527.2 in Q4 2025.
- On a quarterly basis, Other Non-Current Assets fell 28.18% year-over-year to $727527.2 in Q4 2025; TTM through Dec 2025 was $727527.2, a 28.18% decrease from a year earlier, with the FY2025 full-year figure at $727527.2, down 28.18% from the prior year.
- Other Non-Current Assets was $727527.2 for Q4 2025 at Abivax, down from $902516.8 in the prior quarter.
- The five-year high for Other Non-Current Assets was $2.5 million in Q4 2023, with the low at $727527.2 in Q4 2025.
- Average Other Non-Current Assets over 4 years is $1.2 million, with a median of $1.0 million recorded in 2024.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Assets jumped 135.93% in 2023, then tumbled 59.42% in 2024.
- Over 4 years, Other Non-Current Assets stood at $1.1 million in 2022, then surged by 135.93% to $2.5 million in 2023, then tumbled by 59.42% to $1.0 million in 2024, then slipped by 28.18% to $727527.2 in 2025.
- The last three Other Non-Current Assets figures came in at $727527.2 (Q4 2025), $902516.8 (Q1 2025), and $1.0 million (Q4 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.37 Bn | 197.38 Bn | 7.24 Bn | 12.98 Bn |
| 2 | Gilead Sciences | 181.12 Bn | 177.94 Bn | 6.22 Bn | 4.75 Bn |
| 3 | Vertex Pharmaceuticals | 132.11 Bn | 124.26 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn | 2.31 Bn |
| 5 | Argenx Se | 61.69 Bn | 56.50 Bn | 1.37 Bn | 124.00 Mn |
| 6 | Moderna | 54.62 Bn | 49.48 Bn | 52.00 Mn | 618.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.14 Bn | 30.84 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn | 831.80 Mn |
| 9 | Roivant Sciences | 30.09 Bn | 30.09 Bn | 1.16 Mn | 29.59 Mn |
| 10 | Abivax | 10.92 Bn | 10.92 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 727,527.20 |
| Mar 31, 2025 | 902,516.85 |
| Dec 31, 2024 | 1.01 Mn |
| Jun 30, 2024 | 1.21 Mn |
| Dec 31, 2023 | 2.50 Mn |
| Dec 31, 2022 | 1.06 Mn |